Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Oncology · The big question

Customizing care for the painful skin side effects of cancer drugs

Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review.

Editorial illustration for Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review.
Editorial illustration

Summary

Life-saving cancer drugs often come with a harsh side effect: severe skin reactions. These skin issues can be so debilitating that some patients struggle to stick with their treatments. To figure out the best ways to soothe and prevent these conditions, researchers recently conducted a scoping review, which is a broad analysis of existing research. They systematically mapped out data from 51 different clinical studies to see which interventions actually work for specific drug-induced skin problems.

The main takeaway is that treating these skin reactions requires a highly customized approach because different drugs damage the skin in completely different ways. For example, cancer medications called EGFR inhibitors often cause an inflammatory rash. The review found this is best prevented using a combination of specific antibiotics, like tetracyclines or macrolides, paired with topical steroid creams. Conversely, a chemotherapy drug named capecitabine can cause a painful condition called hand-foot syndrome. For this issue, researchers found success using COX-2 inhibitors, which are targeted anti-inflammatory drugs, as well as methylcobalamin, a form of vitamin B12 that has shown strong results in late-stage clinical trials.

Ultimately, the researchers concluded that doctors must ditch the standard, universal approach to skin care. Instead, matching the treatment to the specific biological mechanism of the skin reaction is the most effective strategy. Readers should note that because this is a scoping review, the findings rely on combining previously published studies of varying sizes and designs, rather than data from a brand-new, uniform clinical trial.

Why it matters.

For patients undergoing cancer therapy, quality of life is a crucial factor in their overall health and ability to complete their treatment regimen. Severe rashes and blistered hands or feet are not just cosmetic complaints. They are deeply painful barriers that can force patients to reduce their medication doses or stop taking their life-saving treatments entirely. By pinpointing exactly which targeted therapies prevent specific skin reactions, this research gives oncologists and dermatologists a clear playbook to keep patients comfortable and safely on their prescribed medication.

Moving forward, this shift away from generic lotions toward highly targeted, mechanism-driven supportive care could become a new standard in oncology. As modern cancer treatments become more precise and personalized, the medical community is realizing that the supportive care used to manage their side effects must evolve to be just as sophisticated.

From the source

The story in numbers.

Clinical studies analyzed
51
Toxicity severity threshold targeted and reduced by interventions
Grade ≥ 2
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗